Study aims and goal: An interventional, Phase III clinical trial to evaluate the efficacy and safety of pridopidine in patients with early stage manifest Huntington’s Disease (HD).

No. of study participants and sites: The study aims to recruit 480 participants at sites in: Austria, Canada, Czech Republic, France, Germany, Italy, Netherlands, Poland, Spain, UK, USA

For further information please see the U.S. and EUROPEAN clinical trial registration

*EHDN endorsement: The EHDN endorses protocols it finds to be of a high scientific and ethical quality. The endorsement decision is made on the basis of protocol review and discussion by the EHDN Executive Committee following recommendations from the independent EHDN Scientific and Bioethical Advisory Committee. Trial protocol endorsement should not be viewed as sponsor promotion or recruitment incitement. [EHDN endorsed studies overview]